Precision medicine comes of age in nephrology: identification of novel biomarkers and therapeutic targets for chronic kidney disease

Christina M Wyatt; Detlef Schlondorff

doi:10.1016/j.kint.2016.02.009

Precision medicine comes of age in nephrology: identification of novel biomarkers and therapeutic targets for chronic kidney disease

Kidney Int. 2016 Apr;89(4):734-7. doi: 10.1016/j.kint.2016.02.009.

Authors

Christina M Wyatt¹, Detlef Schlondorff²

Affiliations

¹ Department of Medicine, Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
² Department of Medicine, Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address: detlef.schlondorff@mssm.edu.

PMID: 26994568
DOI: 10.1016/j.kint.2016.02.009

Abstract

The goal of "precision medicine" is to characterize diseases based on the underlying molecular biology, in order to identify specific biomarkers and therapeutic targets that will ultimately improve clinical outcomes. The nephrology research community has developed a strong foundation for precision medicine, and recent publications demonstrate the feasibility of this approach to identify potential biomarkers and therapeutic targets in chronic kidney disease.

Publication types

Editorial

MeSH terms

Animals
Biomarkers / urine*
Humans
Nephrology / trends*
Precision Medicine*
Renal Insufficiency, Chronic / therapy
Renal Insufficiency, Chronic / urine*

Substances

Biomarkers